Objective. Lysyl oxidase (LOX) is an extracellular enzyme that cross-links collagen fibrils. LOX was found to be increased in serum of SSc patients and was suggested to be related to skin fibrosis, yet a vascular source of LOX has been demonstrated in idiopathic pulmonary arterial hypertension (iPAH). We aimed to validate elevated LOX serum levels in SSc and to study its correlation with clinical characteristics and investigate its main source at the tissue level. Methods. A total of 86 established SSc patients were compared with 86 patients with very early diagnosis of systemic sclerosis (VEDOSS), 110 patients with primary RP (PRP) and 80 healthy controls. LOX serum levels were determined by ELISA. Five lung and 12 skin biopsies from SSc patients were stained for LOX and compared with controls. Results. Serum levels of LOX in SSc were significantly higher than in VEDOSS, PRP and healthy controls (P < 0.001). LOX inversely correlated with the diffusing capacity of the lung for carbon monoxide diffusing capacity (DLCO) in diffuse SSc (r =0.376, P = 0.02). Patients with moderate to severe estimated systolic PAH had higher LOX levels (P < 0.01). Lung biopsies demonstrated intense LOX staining in SSc patients with PAH that was predominantly located in the endothelium of the remodelled pulmonary vessels. Conclusion. Serum LOX levels are increased in established SSc and inversely correlate with the DLCO. LOX is elevated in patients with moderate to severe PAH and is located in the proliferating endothelium in lung arterioles, suggesting a possible role for LOX in SSc-associated PAH.

Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension : a multicentre study / Z. Vadasz, A. Balbir Gurman, P. Meroni, D. Farge, Y. Levi, F. Ingegnoli, Y. Braun-Moscovici, I. Rosner, G. Slobodin, M. Rozenbaum, N. Jiries, L. Kaly, N. Boulman, K. Zilber, S. Ginsberg, A. Awisat, Y. Goldberg, M. Lurie, M. Ghigna, C. Guignabert, M. Humbert, D. Rimar. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 58:9(2019 Sep 01), pp. 1547-1555. [10.1093/rheumatology/kez035]

Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension : a multicentre study

P. Meroni;F. Ingegnoli;
2019

Abstract

Objective. Lysyl oxidase (LOX) is an extracellular enzyme that cross-links collagen fibrils. LOX was found to be increased in serum of SSc patients and was suggested to be related to skin fibrosis, yet a vascular source of LOX has been demonstrated in idiopathic pulmonary arterial hypertension (iPAH). We aimed to validate elevated LOX serum levels in SSc and to study its correlation with clinical characteristics and investigate its main source at the tissue level. Methods. A total of 86 established SSc patients were compared with 86 patients with very early diagnosis of systemic sclerosis (VEDOSS), 110 patients with primary RP (PRP) and 80 healthy controls. LOX serum levels were determined by ELISA. Five lung and 12 skin biopsies from SSc patients were stained for LOX and compared with controls. Results. Serum levels of LOX in SSc were significantly higher than in VEDOSS, PRP and healthy controls (P < 0.001). LOX inversely correlated with the diffusing capacity of the lung for carbon monoxide diffusing capacity (DLCO) in diffuse SSc (r =0.376, P = 0.02). Patients with moderate to severe estimated systolic PAH had higher LOX levels (P < 0.01). Lung biopsies demonstrated intense LOX staining in SSc patients with PAH that was predominantly located in the endothelium of the remodelled pulmonary vessels. Conclusion. Serum LOX levels are increased in established SSc and inversely correlate with the DLCO. LOX is elevated in patients with moderate to severe PAH and is located in the proliferating endothelium in lung arterioles, suggesting a possible role for LOX in SSc-associated PAH.
biomarkers; fibrosis; lysyl oxidase; pulmonary arterial hypertension; systemic sclerosis; vasculopathy
Settore MED/16 - Reumatologia
15-feb-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Doron.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 898.41 kB
Formato Adobe PDF
898.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
kez035.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 908.11 kB
Formato Adobe PDF
908.11 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/626660
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact